202 related articles for article (PubMed ID: 23049700)
1. Increased immunogenicity and protective efficacy of influenza M2e fused to a tetramerizing protein.
Andersson AM; Håkansson KO; Jensen BA; Christensen D; Andersen P; Thomsen AR; Christensen JP
PLoS One; 2012; 7(10):e46395. PubMed ID: 23049700
[TBL] [Abstract][Full Text] [Related]
2. Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin.
Stepanova LA; Kotlyarov RY; Kovaleva AA; Potapchuk MV; Korotkov AV; Sergeeva MV; Kasianenko MA; Kuprianov VV; Ravin NV; Tsybalova LM; Skryabin KG; Kiselev OI
PLoS One; 2015; 10(3):e0119520. PubMed ID: 25799221
[TBL] [Abstract][Full Text] [Related]
3. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin.
Huleatt JW; Nakaar V; Desai P; Huang Y; Hewitt D; Jacobs A; Tang J; McDonald W; Song L; Evans RK; Umlauf S; Tussey L; Powell TJ
Vaccine; 2008 Jan; 26(2):201-14. PubMed ID: 18063235
[TBL] [Abstract][Full Text] [Related]
4. [Immunogenicity of recombinant proteins including ectodomain of M2 influenza virus A].
Stepanova LA; Kovaleva AA; Potapchuk MV; Korotkov AV; Kupriianov VV; Blokhina EA; Kotliarov RIu; Tsybalova LM
Vopr Virusol; 2013; 58(3):21-5. PubMed ID: 24006628
[TBL] [Abstract][Full Text] [Related]
5. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.
Tsybalova LM; Stepanova LA; Kuprianov VV; Blokhina EA; Potapchuk MV; Korotkov AV; Gorshkov AN; Kasyanenko MA; Ravin NV; Kiselev OI
Vaccine; 2015 Jun; 33(29):3398-406. PubMed ID: 25976545
[TBL] [Abstract][Full Text] [Related]
6. A lipopeptide based on the M2 and HA proteins of influenza A viruses induces protective antibody.
Pejoski D; Zeng W; Rockman S; Brown LE; Jackson DC
Immunol Cell Biol; 2010 Jul; 88(5):605-11. PubMed ID: 20177411
[TBL] [Abstract][Full Text] [Related]
7. Universal Live-Attenuated Influenza Vaccine Candidates Expressing Multiple M2e Epitopes Protect Ferrets against a High-Dose Heterologous Virus Challenge.
Mezhenskaya D; Isakova-Sivak I; Matyushenko V; Donina S; Rekstin A; Sivak K; Yakovlev K; Katelnikova A; Kryshen K; Makarov V; Rudenko L
Viruses; 2021 Jun; 13(7):. PubMed ID: 34209093
[TBL] [Abstract][Full Text] [Related]
8. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection.
El Bakkouri K; Descamps F; De Filette M; Smet A; Festjens E; Birkett A; Van Rooijen N; Verbeek S; Fiers W; Saelens X
J Immunol; 2011 Jan; 186(2):1022-31. PubMed ID: 21169548
[TBL] [Abstract][Full Text] [Related]
9. An M2e-based synthetic peptide vaccine for influenza A virus confers heterosubtypic protection from lethal virus challenge.
Ma JH; Yang FR; Yu H; Zhou YJ; Li GX; Huang M; Wen F; Tong G
Virol J; 2013 Jul; 10():227. PubMed ID: 23834899
[TBL] [Abstract][Full Text] [Related]
10. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e.
Park KS; Seo YB; Lee JY; Im SJ; Seo SH; Song MS; Choi YK; Sung YC
Vaccine; 2011 Jul; 29(33):5481-7. PubMed ID: 21664216
[TBL] [Abstract][Full Text] [Related]
11. Protective efficacy of a broadly cross-reactive swine influenza DNA vaccine encoding M2e, cytotoxic T lymphocyte epitope and consensus H3 hemagglutinin.
Wang B; Yu H; Yang FR; Huang M; Ma JH; Tong GZ
Virol J; 2012 Jun; 9():127. PubMed ID: 22738661
[TBL] [Abstract][Full Text] [Related]
12. Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies.
De Filette M; Martens W; Smet A; Schotsaert M; Birkett A; Londoño-Arcila P; Fiers W; Saelens X
Vaccine; 2008 Dec; 26(51):6503-7. PubMed ID: 18835315
[TBL] [Abstract][Full Text] [Related]
13. Sublingual immunization with M2-based vaccine induces broad protective immunity against influenza.
Shim BS; Choi YK; Yun CH; Lee EG; Jeon YS; Park SM; Cheon IS; Joo DH; Cho CH; Song MS; Seo SU; Byun YH; Park HJ; Poo H; Seong BL; Kim JO; Nguyen HH; Stadler K; Kim DW; Hong KJ; Czerkinsky C; Song MK
PLoS One; 2011; 6(11):e27953. PubMed ID: 22140491
[TBL] [Abstract][Full Text] [Related]
14. Potential recombinant vaccine against influenza A virus based on M2e displayed on nodaviral capsid nanoparticles.
Yong CY; Yeap SK; Ho KL; Omar AR; Tan WS
Int J Nanomedicine; 2015; 10():2751-63. PubMed ID: 25897220
[TBL] [Abstract][Full Text] [Related]
15. Combination of M2e peptide with stalk HA epitopes of influenza A virus enhances protective properties of recombinant vaccine.
Tsybalova LM; Stepanova LA; Shuklina MA; Mardanova ES; Kotlyarov RY; Potapchuk MV; Petrov SA; Blokhina EA; Ravin NV
PLoS One; 2018; 13(8):e0201429. PubMed ID: 30138320
[TBL] [Abstract][Full Text] [Related]
16. Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2.
Mozdzanowska K; Feng J; Eid M; Kragol G; Cudic M; Otvos L; Gerhard W
Vaccine; 2003 Jun; 21(19-20):2616-26. PubMed ID: 12744898
[TBL] [Abstract][Full Text] [Related]
17. Protection against influenza A virus by vaccination with a recombinant fusion protein linking influenza M2e to human serum albumin (HSA).
Mu X; Hu K; Shen M; Kong N; Fu C; Yan W; Wei A
J Virol Methods; 2016 Feb; 228():84-90. PubMed ID: 26615805
[TBL] [Abstract][Full Text] [Related]
18. Tetramerizing tGCN4 domain facilitates production of Influenza A H1N1 M2e higher order soluble oligomers that show enhanced immunogenicity
Samal S; Shrivastava T; Sonkusre P; Rizvi ZA; Kumar R; Ahmed S; Vishwakarma P; Yadav N; Bansal M; Chauhan K; Pokhrel S; Das S; Tambare P; Awasthi A
J Biol Chem; 2020 Oct; 295(42):14352-14366. PubMed ID: 32817314
[TBL] [Abstract][Full Text] [Related]
19. Engineering of the PapMV vaccine platform with a shortened M2e peptide leads to an effective one dose influenza vaccine.
Carignan D; Thérien A; Rioux G; Paquet G; Gagné ML; Bolduc M; Savard P; Leclerc D
Vaccine; 2015 Dec; 33(51):7245-7253. PubMed ID: 26549362
[TBL] [Abstract][Full Text] [Related]
20. Protective efficacy of a bacterially produced modular capsomere presenting M2e from influenza: extending the potential of broadly cross-protecting epitopes.
Wibowo N; Hughes FK; Fairmaid EJ; Lua LH; Brown LE; Middelberg AP
Vaccine; 2014 Jun; 32(29):3651-5. PubMed ID: 24795225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]